Spots Global Cancer Trial Database for Imatinib Mesylate in Combination With Docetaxel for Advanced, Platinum-Refractory Ovarian Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Imatinib Mesylate in Combination With Docetaxel for Advanced, Platinum-Refractory Ovarian Cancer
Official Title: Imatinib Mesylate (Gleevec庐, STI571) in Combination With Docetaxel (Taxotere) for the Treatment of Advanced, Platinum-Refractory Ovarian Cancer and Primary Peritoneal Carcinomatosis: Hoosier Oncology Group GYN03-62
Study ID: NCT00216112
Conditions
Study Description
Brief Summary: Imatinib mesylate is an inhibitor of the receptor tyrosine kinases for platelet-derived growth factor (PDGF) and stem cell factor (SCF), c-Kit, and inhibits PDGF- and SCF-mediated cellular events. Docetaxel promotes cell growth arrest by inhibiting the deassembly of tubulin and by promoting at the same time microtubule assembly. Docetaxel has single agent activity in ovarian cancer with response rates of 30-40% in the platinum refractory setting. The combination of imatinib mesylate and docetaxel has potential synergistic effects, based on previous reports showing synergy in-vitro and in-vivo between PDGFR inhibitors or PI3K inhibitors and taxane chemotherapy. This trial will investigate the efficacy the combination of imatinib mesylate and docetaxel in treating patients with advanced, platinum-refractory ovarian cancer and primary peritoneal carcinomatosis.
Detailed Description: OUTLINE: This is a multi-center study. Submit tumor and serum samples for central review * Imatinib 600 mg (orally qd); * Docetaxel 30mg/m2 (4 of 6 weeks);1 cycle = 6 weeks * Evaluate every other cycle Each cycle will begin only when the granulocyte count is \> 1,500/mm3 and the platelet count is \> 100,000/mm3 and any other treatment-related toxicities are \< grade 1. If the toxicity is not resolved to grade 0 or 1 after three weeks, the patient will be withdrawn from the study. For days 8, 15, and 22 patients must have an absolute neutrophil count \> 1,000/mm3 or greater and platelet count \> 75,000/mm3. Imatinib mesylate can be administered if platelets \>20,000 and ANC \>500. ECOG performance status 0 or 1 Hematopoietic:路 * ANC \> 1,500/mm3路 * Platelets \> 100,000 mm3路 * Hgb \> 8g/dl Hepatic:路 * Albumin\>3gm/dL路 * Total bilirubin \< ULN路 * Maximum Alk Phos: \>2.5x but \< 5x ULN Renal:路 * Creatinine \< 1.5 x ULN路(by Cockroft and Gault) Cardiovascular:路 * No grade III/IV cardiac problems as defined by the New York Heart Association Criteria. (i.e., congestive heart failure, myocardial infarction within 6 months prior to beginning protocol therapy) Pulmonary:路 * Not specified
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: FEMALE
Healthy Volunteers: No
Locations
Medical & Surgical Specialists, LLC, Galesburg, Illinois, United States
Elkhart Clinic, Elkhart, Indiana, United States
Oncology Hematology Associates of SW Indiana, Evansville, Indiana, United States
Fort Wayne Oncology & Hematology, Inc, Fort Wayne, Indiana, United States
Indiana University Cancer Center, Indianapolis, Indiana, United States
Arnett Cancer Care, Lafayette, Indiana, United States
Medical Consultants, P.C., Muncie, Indiana, United States
Center for Cancer Care, Inc., P.C., New Albany, Indiana, United States
AP&S Clinic, Terre Haute, Indiana, United States
Contact Details
Name: Daniela Matei, M.D.
Affiliation: Hoosier Oncology Group, LLC
Role: STUDY_CHAIR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
